Öner BALBAY, Ali Nihat ANNAKKAYA, Cahit BİLGİN, Özlem YAVUZ, İsmet BULUT, Emel KURT, Abdurrahman COŞKUN, Ramazan MEMİŞOĞULLARI

Evaluation of Tumor Markers in Asthma Patients

Background: Although tumor markers have been used as biomarkers for monitoring response to therapy and detecting early relapse in malignancies, it is well known that most tumor marker increases are not specific enough to be used for diagnosis of cancer. Aim: The aim of this study was to investigate the serum concentrations of a -fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, CA 125, CA 15-3 and IgE in asthma patients. Materials and Methods: Thirty-five newly diagnosed asthmatic patients and 14 healthy subjects were included into the study. Blood samples were drawn from antecubital vein of asthma patients and control subjects. Serum AFP, CEA, CA 125, CA 15-3 and CA 19-9 levels were determined by chemiluminescent and IgE levels by electrochemiluminescent immunometric method on automatic hormone analyzers. Results: Serum levels of AFP, CEA, CA 19-9, CA 125, and CA 15-3 of asthma patients were not significantly different when compared with the control group. In asthma patients, there was a significant negative correlation between serum IgE and CA 125 (r = -0.401; p = 0.017) and a positive correlation between CA 125 and CA 15-3 (r = 0.368; p = 0.029). Conclusions: We concluded that in asthma patients' sera, AFP, CEA, CA 125, CA 19-9 and CA 15-3 levels were not different from control subjects. Elevation in any of these tumor markers in asthma patients should be a sign for clinicians to evaluate patients for additional diseases.

Anahtar Kelimeler:

Asthma, AFP, CA 125, CA 15-3, CA 19-9, CEA

Evaluation of Tumor Markers in Asthma Patients

Keywords:

Asthma, AFP, CA 125, CA 15-3, CA 19-9, CEA,

PDF

___

1. Chan DW, Booth RA. Tumor markers. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Missouri: Elsevier Saunders Inc; 2006. p.745-795.
2. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1988; 13: 179-187.
3. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350-355.
4. Montefort S, Roberts JA, Beasley R, Holgate ST, Roche WR. The site of disruption of the bronchial epithelium in asthmatic and non-asthmatic subjects. Thorax 1992; 47: 499-503.
5. Davis DE. The bronchial epithelium. Translating gene and environment interactions in asthma. Curr Opin Allergy Clin Immunol 2001; 1: 67-71.
6. Global Strategy for Asthma Management and Prevention. NIH Publication GINA Workshop Report. Available from: URL: http:// www.ginasthma.org
7. Rubin H. The significance of biological heterogeneity. Cancer Metastasis Rev 1990; 9: 1-20.
8. Pritzker KPH. Cancer biomarkers: easier said than done. Clin Chem 2002; 48: 1147-1150.
9. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990; 3: 507-511.
10. Stevens DP, Mackay IR. Increased carcinoembryonic antigens in heavy cigarette smokers. Lancet 1973; 2: 1238-1239.
11. Beaudonnet A, Gounon G, Pichot J, Revenant MC. Sex- and agerelated influences on carcinoembryonic antigen in blood. Clin Chem 1981; 27: 771.
12. Touitou Y, Proust J, Klinger E, Nakache JP, Huard D, Sachet A. Cumulative effects of age and pathology on plasma carcinoembryonic antigen in an unselected elderly population. Eur J Cancer Clin Oncol 1984; 20: 369-374.
13. Sanguinetti CM, Riccioni G, Marchesani F, Pela R, Cecarini L. Bronchoalveolar lavage fluid level of carcinoembryonic antigen in the diagnosis of peripheral lung cancer. Monaldi Arch Chest Dis 1995; 50: 177-182.
14. Maeda Y, Hizawa N, Fukui Y, Nagai K, Kikuchi E, Takahashi D et al. Concentrations of carcinoembryonic antigen in serum and bronchoalveolar lavage fluid of asthmatic patients with mucoid impaction. Nihon Kokyuki Gakkai Zasshi 2004; 42: 988-993.
15. Takayama S, Kataoka N, Usui Y, Inase N, Natori Y, Nakayama M et al. CA 19-9 in patients with benign pulmonary diseases. Nihon Kyobu Shikkan Gakkai Zasshi 1990; 28: 1326-1331.